Immediate-Release and Delayed-Release Segment Inputs

Why Input Timing and Location Matter

A segmental absorption model must specify not only how drug dissolves, transits, and is absorbed, but also when and where drug enters the modeled lumen. An immediate-release dose is often represented as an initial amount in the first modeled compartment. A delayed-release dose may enter after a lag, or be delivered according to a release-rate profile. A formulation designed to release in a downstream region can instead be represented by an input to that segment. These choices alter the time available for transit and absorption in each region.

Timing and location are separate modeling choices. A dose can be delayed and then enter the first segment, or it can be released later into a downstream segment. The input representation should reflect the formulation behavior the model is intended to describe; it should not be selected merely because it makes a simulated profile fit more easily.

Representing Formulation Input in Segment Balances

Let \(M_i(t)\) denote the luminal drug mass in segment \(i\), \(k_{\mathrm{tr},i}\) its first-order transit rate constant, and \(k_{\mathrm{a},i}\) its first-order absorption rate constant. Let \(Q_i(t)\) be the transit inflow from the preceding segment, with \(Q_1(t)=0\) if there is no modeled upstream segment. Let \(u_i(t)\) be the formulation release rate directly into segment \(i\), measured in mass per time. A segment balance is

\frac{dM_i(t)}{dt} = Q_i(t)+u_i(t) - \left(k_{\mathrm{tr},i}+k_{\mathrm{a},i}\right)M_i(t).

For a nonterminal segment, its transit outflow \(k_{\mathrm{tr},i}M_i(t)\) becomes an inflow to the next segment. The absorption rate from segment \(i\) is \(k_{\mathrm{a},i}M_i(t)\). For a terminal segment, transit outflow represents drug leaving the modeled gut. These first-order balances assume that the rate constants are constant over the interval considered, the drug is well mixed within each segment, and the specified pathways account for drug loss. If degradation or another loss is modeled, it must be added explicitly.

Definition: An input is a specified amount or release rate of drug added to a segmental luminal state. A bolus input of \(D\) mg at time \(t_0\) can be represented by a jump \(M_j(t_0^+)=M_j(t_0^-)+D\). A distributed release input is represented by a rate \(u_j(t)\); its delivered amount over an interval is the integral of that rate over time.

For a release profile delivering a fraction \(f\) of a dose \(D\), a convenient representation is \(u_j(t)=fDg(t-t_{\mathrm{lag}})\) for \(t\geq t_{\mathrm{lag}}\), and zero before the lag. Here \(g\) is a nonnegative release-rate shape with units of inverse time and total integral one. Thus, the input delivers \(fD\) mg, not \(fD\) mg per hour. If the model includes several release locations, the amounts allocated to them must sum to the intended dose, unless a separate unmodeled fraction is explicitly specified.

How Input Location Changes Transit and Absorption

The effect of segment location can be seen from the competing first-order processes in one segment. Suppose a bolus \(D\) enters an otherwise empty segment at time zero, and there is no additional input. The amount remaining after elapsed time \(t\) is \(D\exp[-(k_{\mathrm{a}}+k_{\mathrm{tr}})t]\). Integrating the absorption rate over time gives the eventual amount absorbed in that segment:

\int_0^\infty k_{\mathrm{a}}D \exp[-(k_{\mathrm{a}}+k_{\mathrm{tr}})t]\,dt = D\frac{k_{\mathrm{a}}}{k_{\mathrm{a}}+k_{\mathrm{tr}}}.

The remaining fraction, \(k_{\mathrm{tr}}/(k_{\mathrm{a}}+k_{\mathrm{tr}})\), transits onward. This result assumes constant first-order rates and no other drug loss. It is useful for comparing input locations: material released downstream bypasses upstream absorption opportunities, but may also avoid upstream transit or other modeled limitations. Its eventual absorption depends on the rates in the segment it reaches and in any segments that follow.

Worked Example: Immediate Release Into the First Segment

Hypothetical model. A 100 mg immediate-release dose enters segment 1 at time zero. In segment 1, \(k_{\mathrm{a},1}=0.20\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr},1}=0.80\ \mathrm{h}^{-1}\). Drug transiting onward enters terminal segment 2, where \(k_{\mathrm{a},2}=0.50\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr},2}=0.50\ \mathrm{h}^{-1}\). Assume no further input or other drug loss.

In segment 1, the total removal rate is \(0.20+0.80=1.00\ \mathrm{h}^{-1}\). The amount absorbed there is

100\ \mathrm{mg}\times \frac{0.20\ \mathrm{h}^{-1}}{1.00\ \mathrm{h}^{-1}} =20.0\ \mathrm{mg}.

The amount transiting to segment 2 is \(100-20.0=80.0\) mg. In segment 2, the absorption fraction is \(0.50/(0.50+0.50)=0.50\), so \(80.0\times0.50=40.0\) mg is absorbed there and \(40.0\) mg exits the modeled gut. Total absorption is \(20.0+40.0=60.0\) mg. The mass balance is \(60.0\) mg absorbed plus \(40.0\) mg exiting, equal to the 100 mg dose.

Delayed Release: Shift the Input in Time

A delayed-release input can be represented as a bolus jump at a specified lag or as a release profile that begins after the lag. Before release begins, the delayed portion contributes no luminal mass to the receiving segment. Once released, it experiences the transit and absorption processes from its receiving location onward. This makes the time origin important: a profile can be reported relative to administration or relative to release, and those are not the same elapsed time.

Worked Example: A Delayed Bolus Into a Terminal Segment

Hypothetical model. An 80 mg dose is released as a bolus into terminal segment 2 at \(t_{\mathrm{lag}}=2.0\) h after administration. In this segment, \(k_{\mathrm{a},2}=0.50\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr},2}=0.50\ \mathrm{h}^{-1}\). There is no input before the lag. Find the amount absorbed from segment 2 by \(t=4.0\) h after administration.

Only \(4.0-2.0=2.0\) h have elapsed since release. The total removal rate is \(1.00\ \mathrm{h}^{-1}\), so the cumulative absorption over those two hours is

80\ \mathrm{mg}\times \frac{0.50\ \mathrm{h}^{-1}}{1.00\ \mathrm{h}^{-1}} \left(1-\exp[-(1.00\ \mathrm{h}^{-1})(2.0\ \mathrm{h})]\right) = 34.59\ \mathrm{mg}.

Thus, 34.59 mg has been absorbed from this segment by 4.0 h after administration. In the eventual limit, \(80\times0.50=40.0\) mg is absorbed and 40.0 mg exits the modeled gut. The lag shifts the response later; it does not change the eventual fraction absorbed under these constant-rate assumptions. A different receiving segment or different rate constants could change that fraction.

Specified Downstream Input: Change the Receiving Segment

A release targeted to a modeled downstream region can be represented by adding its input to that segment’s balance, rather than routing all of it through the upstream segments. This is not the same as increasing the upstream transit rate: upstream segments receive no portion of the downstream input to absorb or transit. If some of a dose releases upstream and some downstream, represent those portions as separate inputs and check that their total matches the dose.

Worked Example: Splitting a Dose Between Two Release Locations

Hypothetical model. Of a 100 mg dose, 30 mg is released immediately into segment 1 and 70 mg immediately into terminal segment 2. Segment 1 has \(k_{\mathrm{a},1}=0.20\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr},1}=0.80\ \mathrm{h}^{-1}\). Segment 2 has \(k_{\mathrm{a},2}=0.50\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr},2}=0.50\ \mathrm{h}^{-1}\). Assume constant rates and no other loss.

From the 30 mg entering segment 1, the absorbed amount is

30\ \mathrm{mg}\times\frac{0.20}{0.20+0.80} =6.00\ \mathrm{mg}.

The remaining \(30-6.00=24.0\) mg transits to segment 2. Segment 2 therefore receives \(70+24.0=94.0\) mg in total. Half is absorbed there, giving \(94.0\times0.50=47.0\) mg, while 47.0 mg exits. Total absorption is \(6.00+47.0=53.0\) mg, and \(53.0+47.0=100\) mg accounts for the full dose.

For comparison, if all 100 mg were released into segment 1 under the same rates, 20.0 mg would be absorbed there and 80.0 mg would reach segment 2; 40.0 mg would then be absorbed and 40.0 mg would exit. Total absorption would be 60.0 mg. In this hypothetical model, shifting part of the dose downstream lowers total absorption from 60.0 to 53.0 mg because that portion bypasses the first segment’s absorption opportunity. This is a consequence of the assumed rates, not a general prediction for every formulation.

Mass Balance, Diagnostics, and Modeling Choices

With no degradation or other loss, the mass-conservation check for the full model is that the cumulative dose input equals the luminal mass remaining plus cumulative absorption plus cumulative outflow from the terminal modeled segment. Transfers between adjacent segments cancel when the segment balances are summed: outflow from one is inflow to the next. This check applies whether input is an initial amount, a delayed bolus, or a distributed release rate.

Check the input amount. For a rate input, integrate \(u_i(t)\) over its release period. Confirm that all input amounts sum to the modeled dose fraction.
Check timing and location. Verify that the input is zero before a specified lag and that it enters the intended segment. A time shift and a change of receiving segment are distinct model changes.
Avoid double-counting. Do not enter the same dose both as an initial luminal amount and as a release-rate input. If the model starts with nonzero mass, include that mass once in the dose accounting.
Check numerical behavior. A simulated mass that becomes negative, a delayed input that appears before its lag, or a large unexplained mass-balance error can indicate an implementation or solver problem. At a bolus time, apply the specified jump consistently; for a smooth release profile, check that its integral is correct.

The main alternatives are different representations of the same input information. An initial condition is convenient for an immediate bolus at the model start. A time-dependent source is suitable for a lagged or extended release profile. A source in a downstream segment represents a specified release location. These are not interchangeable unless they encode the same timing and receiving location. A distributed release profile also requires a defensible choice of its shape; a convenient mathematical profile is not, by itself, evidence about the actual formulation.

These representations assume that the release process can be prescribed independently of the luminal drug states. If release depends on conditions that change with time or location, a fixed input profile may be inadequate and a more explicit release mechanism may be needed. Segment inputs also do not establish that a physical formulation releases at precisely the modeled location or time. Those are assumptions to assess against available formulation and regional data.

Key takeaway: Specify each input by its amount, time course, and receiving segment. Then verify dose accounting and follow the input through the segment balances; absorption depends on the rates encountered after release, not on the input label alone.

Check Your Understanding

Work each problem from the stated model assumptions. Solutions are included below.

A 50 mg bolus enters a segment with \(k_{\mathrm{a}}=0.30\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr}}=0.70\ \mathrm{h}^{-1}\). How much is eventually absorbed in that segment, and how much transits onward?
A 40 mg bolus enters a terminal segment at \(t=1.5\) h. Its absorption and outflow rates are \(0.60\ \mathrm{h}^{-1}\) and \(0.40\ \mathrm{h}^{-1}\), respectively. How much is absorbed from that segment by \(t=2.5\) h after administration?
A 100 mg dose is split between 80 mg entering an upstream segment and 20 mg entering a terminal downstream segment. In the upstream segment, \(k_{\mathrm{a}}=0.25\ \mathrm{h}^{-1}\) and \(k_{\mathrm{tr}}=0.75\ \mathrm{h}^{-1}\). In the terminal segment, absorption and outflow rates are \(0.40\ \mathrm{h}^{-1}\) and \(0.60\ \mathrm{h}^{-1}\). What is the total eventual absorption?
A model assigns 25 mg as the initial amount in segment 1 and also specifies a release-rate profile whose integral is 25 mg for that same portion of the dose. What is the problem, and how should it be corrected?

Solutions. (1) The total rate is \(0.30+0.70=1.00\ \mathrm{h}^{-1}\). Absorption is \(50(0.30/1.00)=15.0\) mg, and transit onward is \(50-15.0=35.0\) mg. (2) One hour has elapsed since release. The absorbed amount is \(40[0.60/(0.60+0.40)](1-\exp[-1.00(1.0)])=15.17\) mg. (3) The upstream segment absorbs \(80(0.25/1.00)=20.0\) mg and passes 60.0 mg onward. The terminal segment receives \(60.0+20.0=80.0\) mg and absorbs \(80.0[0.40/(0.40+0.60)]=32.0\) mg. Total absorption is \(20.0+32.0=52.0\) mg. (4) The same 25 mg is counted twice, so the modeled input for that portion is 50 mg. Represent it once—as an initial amount or as a release-rate input—and ensure the full set of inputs matches the intended dose.